Cargando…

Rehospitalization burden and morbidity risk in patients with heart failure with mid‐range ejection fraction

AIMS: Heart failure with mid‐range ejection fraction (HFmrEF) has been proposed as a distinct HF phenotype, but whether patients on this category fare worse, similarly, or better than those with HF with reduced EF (HFrEF) or preserved EF (HFpEF) in terms of rehospitalization risks over time remains...

Descripción completa

Detalles Bibliográficos
Autores principales:	Santas, Enrique, de la Espriella, Rafael, Palau, Patricia, Miñana, Gema, Amiguet, Martina, Sanchis, Juan, Lupón, Josep, Bayes‐Genís, Antoni, Chorro, Francisco Javier, Núñez Villota, Julio
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2020
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7261530/ https://www.ncbi.nlm.nih.gov/pubmed/32212327 http://dx.doi.org/10.1002/ehf2.12683

Ejemplares similares

Right Ventricular Dysfunction Staging System for Mortality Risk Stratification in Heart Failure with Preserved Ejection Fraction
por: Santas, Enrique, et al.
Publicado: (2020)

Sex‐Related Differences in Mortality Following Admission for Acute Heart Failure Across the Left Ventricular Ejection Fraction Spectrum
por: Santas, Enrique, et al.
Publicado: (2021)

Carbohydrate antigen 125 and risk of heart failure readmissions in patients with heart failure and preserved ejection fraction
por: Miñana, Gema, et al.
Publicado: (2022)

Effect of insulin on readmission for heart failure following a hospitalization for acute heart failure
por: Bertomeu‐Gonzalez, Vicente, et al.
Publicado: (2020)

Dapagliflozin and short-term changes on circulating antigen carbohydrate 125 in heart failure with reduced ejection fraction
por: Amiguet, Martina, et al.
Publicado: (2023)

Intrarenal venous flow in cardiorenal syndrome: a shining light into the darkness
por: de la Espriella‐Juan, Rafael, et al.
Publicado: (2018)

Role of PCSK9 in the course of ejection fraction change after ST‐segment elevation myocardial infarction: a pilot study
por: Miñana, Gema, et al.
Publicado: (2020)

Transitioning from Preclinical to Clinical Heart Failure with Preserved Ejection Fraction: A Mechanistic Approach
por: Bayes-Genis, Antoni, et al.
Publicado: (2020)

Serum Neprilysin and Recurrent Admissions in Patients With Heart Failure
por: Núñez, Julio, et al.
Publicado: (2017)

Beta‐blockers withdrawal in patients with heart failure with preserved ejection fraction and chronotropic incompetence: Effect on functional capacity rationale and study design of a prospective, randomized, controlled trial (The Preserve‐HR trial)
por: Palau, Patricia, et al.
Publicado: (2020)

Venous Leg Compression for Tissue Decongestion in Patients With Worsening Congestive Heart Failure
por: Civera, Jose, et al.
Publicado: (2022)

Noninvasive Imaging Estimation of Myocardial Iron Repletion Following Administration of Intravenous Iron: The Myocardial‐IRON Trial
por: Núñez, Julio, et al.
Publicado: (2020)

Renal function dynamics following co‐administration of sacubitril/valsartan and empagliflozin in patients with heart failure and type 2 diabetes
por: de la Espriella, Rafael, et al.
Publicado: (2020)

Predictive biomarkers for death and rehospitalization in comorbid frail elderly heart failure patients
por: Pacho, Cristina, et al.
Publicado: (2018)

Prognostic value of reverse remodelling criteria in heart failure with reduced or mid‐range ejection fraction
por: Aimo, Alberto, et al.
Publicado: (2021)

The influence of sex and body mass index on the association between soluble neprilysin and risk of heart failure hospitalizations
por: Núñez, Julio, et al.
Publicado: (2021)

Biomarkers in Heart Failure with Preserved Ejection Fraction
por: Bayes-Genis, Antoni, et al.
Publicado: (2022)

Short‐Term Changes in Left and Right Ventricular Cardiac Magnetic Resonance Feature Tracking Strain Following Ferric Carboxymaltose in Patients With Heart Failure: A Substudy of the Myocardial‐IRON Trial
por: del Canto, Irene, et al.
Publicado: (2022)

Short‐term changes in left and right systolic function following ferric carboxymaltose: a substudy of the Myocardial‐IRON trial
por: Santas, Enrique, et al.
Publicado: (2020)

Left ventricular ejection fraction recovery in patients with heart failure treated with intravenous iron: a pilot study
por: Núñez, Julio, et al.
Publicado: (2016)

Clinical characteristics, one-year change in ejection fraction and long-term outcomes in patients with heart failure with mid-range ejection fraction: a multicentre prospective observational study in Catalonia (Spain)
por: Farré, Nuria, et al.
Publicado: (2017)

Suppression of acute heart failure rehospitalization by biventricular pacing in wide QRS and mid‐range ejection fraction
por: Akamine, Koshiro, et al.
Publicado: (2021)

Prognostic Value of the Interaction between Galectin-3 and Antigen Carbohydrate 125 in Acute Heart Failure
por: Núñez, Julio, et al.
Publicado: (2015)

Incidence, Treatment and Clinical Impact of Iron Deficiency in Chronic Heart Failure: A Longitudinal Analysis
por: Miñana, Gema, et al.
Publicado: (2022)

Coronary Revascularization and Long-Term Survivorship in Chronic Coronary Syndrome
por: Gabaldon-Perez, Ana, et al.
Publicado: (2021)

Can Natriuretic Peptides be Used to Guide Therapy?
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Short-term changes in klotho and FGF23 in heart failure with reduced ejection fraction—a substudy of the DAPA-VO(2) study
por: Mora-Fernández, Carmen, et al.
Publicado: (2023)

Risk of death associated with incident heart failure in patients with known or suspected chronic coronary syndrome
por: Núñez, Julio, et al.
Publicado: (2022)

Heart rate response and functional capacity in patients with chronic heart failure with preserved ejection fraction
por: Domínguez, Eloy, et al.
Publicado: (2018)

The DELIVER Trial: the Beginning of the End of Ejection Fraction Tyranny
por: Bayes-Genis, Antoni
Publicado: (2022)

Circulating neprilysin hypothesis: A new opportunity for sacubitril/valsartan in patients with heart failure and preserved ejection fraction?
por: Lupón, Josep, et al.
Publicado: (2021)

Sacubitril/valsartan affects pulmonary arterial pressure in heart failure with preserved ejection fraction and pulmonary hypertension
por: Codina, Pau, et al.
Publicado: (2022)

Heart Failure with Preserved Ejection Fraction: An Urgent Need for Precision Medicine
por: Miñana, Gema, et al.
Publicado: (2021)

Multi-Biomarker Profiling and Recurrent Hospitalizations in Heart Failure
por: Bayes-Genis, Antoni, et al.
Publicado: (2016)

Decoding empagliflozin’s molecular mechanism of action in heart failure with preserved ejection fraction using artificial intelligence
por: Bayes-Genis, Antoni, et al.
Publicado: (2021)

Biomarkers to Improve Decision-making in Acute Heart Failure
por: de la Espriella, Rafael, et al.
Publicado: (2023)

Characterization and implications of the dynamics of eosinophils in blood and in the infarcted myocardium after coronary reperfusion
por: Rios-Navarro, Cesar, et al.
Publicado: (2018)

Unraveling the Molecular Mechanism of Action of Empagliflozin in Heart Failure With Reduced Ejection Fraction With or Without Diabetes
por: Iborra-Egea, Oriol, et al.
Publicado: (2019)

Pirfenidone as a novel cardiac protective treatment
por: Aimo, Alberto, et al.
Publicado: (2021)

Comorbidities, Fragility, and Quality of Life in Heart Failure Patients With Midrange Ejection Fraction
por: Gastelurrutia, Paloma, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_4ophhpdv150l2hiur65h812095